clozapine

Ligand id: 38

Name: clozapine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: clozapine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 30.87
Molecular weight 326.13
XLogP 4.32
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Boess FG, Monsma FJ, Carolo C, Meyer V, Rudler A, Zwingelstein C, Sleight AJ. (1997)
Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells.
Neuropharmacology36: 713-720. [PMID:9225298]
2. Boess FG, Monsma FJ, Meyer V, Zwingelstein C, Sleight AJ. (1997)
Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor.
Mol Pharmacol52: 515-523. [PMID:9284367]
3. Boess FG, Monsma FJ, Sleight AJ. (1998)
Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor.
J Neurochem71: 2169-2177. [PMID:9798944]
4. Boess FG, Riemer C, Bos M, Bentley J, Bourson A, Sleight AJ. (1998)
The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum.
Mol Pharmacol54: 577-583. [PMID:9730917]
5. Booth RG, Moniri NH, Bakker RA, Choksi NY, Nix WB, Timmerman H, Leurs R. (2002)
A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors.
J Pharmacol Exp Ther302: 328-336. [PMID:12065734]
6. Egan CT, Herrick-Davis K, Teitler M. (1998)
Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.
J Pharmacol Exp Ther286: 85-90. [PMID:9655845]
7. Fitzgerald LW, Conklin DS, Krause CM, Marshall AP, Patterson JP, Tran DP, Iyer G, Kostich WA, Largent BL, Hartig PR. (1999)
High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
J Neurochem72: 2127-2134. [PMID:10217294]
8. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G. (1994)
Expression and pharmacological characterization of the human D3 dopamine receptor.
J Pharmacol Exp Ther268: 417-426. [PMID:8301582]
9. Grailhe R, Grabtree GW, Hen R. (2001)
Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution.
Eur J Pharmacol418: 157-167. [PMID:11343685]
10. Herrick-Davis K, Grinde E, Teitler M. (2000)
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
J Pharmacol Exp Ther295: 226-232. [PMID:10991983]
11. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M. (2004)
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
Naunyn Schmiedebergs Arch Pharmacol370: 114-123. [PMID:15322733]
12. Kobayashi T, Ikeda K, Kumanishi T. (2000)
Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.
Br. J. Pharmacol.129 (8): 1716-22. [PMID:10780978]
13. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW. (1996)
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.
J Neurochem66: 47-56. [PMID:8522988]
14. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A. (1996)
Iloperidone binding to human and rat dopamine and 5-HT receptors.
Eur J Pharmacol317: 417-423. [PMID:8997630]
15. Krobert KA, Bach T, Syversveen T, Kvingedal AM, Levy FO. (2001)
The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution.
Naunyn Schmiedebergs Arch Pharmacol363: 620-632. [PMID:11414657]
16. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. (2003)
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Neuropsychopharmacology28: 519-526. [PMID:12629531]
17. Lahti RA, Evans DL, Stratman NC, Figur LM. (1993)
Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications.
Eur J Pharmacol236: 483-486. [PMID:8102973]
18. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R. (2005)
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
J Pharmacol Exp Ther314: 1310-1321. [PMID:15947036]
19. Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J, Pyati J, Li X, Chai W, Carruthers N, Lovenberg TW. (2001)
Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
Mol Pharmacol59: 420-426. [PMID:11179434]
20. Liu C, Wilson SJ, Kuei C, Lovenberg TW. (2001)
Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
J Pharmacol Exp Ther299: 121-130. [PMID:11561071]
21. Lovenberg TW, Pyati J, Chang H, Wilson SJ, Erlander MG. (2000)
Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles.
J Pharmacol Exp Ther293: 771-778. [PMID:10869375]
22. MacKenzie RG, VanLeeuwen D, Pugsley TA, Shih YH, Demattos S, Tang L, Todd RD, O'Malley KL. (1994)
Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
Eur J Pharmacol266: 79-85. [PMID:7907989]
23. Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G. (1998)
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
J Pharmacol Exp Ther286: 1341-1355. [PMID:9732398]
24. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. (1993)
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
Mol Pharmacol43: 320-327. [PMID:7680751]
25. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ. (1998)
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Eur J Pharmacol355: 245-256. [PMID:9760039]
26. Plassat JL, Amlaiky N, Hen R. (1993)
Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase.
Mol Pharmacol44: 229-236. [PMID:8394987]
27. Purohit A, Smith C, Herrick-Davis K, Teitler M. (2005)
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
Psychopharmacology (Berl)179: 461-469. [PMID:15821958]
28. Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M. (1994)
Cloning and characterisation of the human 5-HT5A serotonin receptor.
FEBS Lett.355: 242-246. [PMID:7988681]
29. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR. (1994)
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
J Pharmacol Exp Ther268: 1403-1410. [PMID:7908055]
30. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC. (1993)
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.
Proc Natl Acad Sci U S A90: 8547-8551. [PMID:8397408]
31. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996)
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Psychopharmacology (Berl)124: 57-73. [PMID:8935801]
32. Shahid M, Walker GB, Zorn SH, Wong EH. (2009)
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
J. Psychopharmacol. (Oxford)23 (1): 65-73. [PMID:18308814]
33. Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. (1993)
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
J Biol Chem268: 18200-18204. [PMID:8394362]
34. Sokoloff P, Andrieux M, Besançon R, Pilon C, Martres M-P, Giros B, Schwartz J-C. (1992)
Pharmacology of human D3 dopamine receptor expressed in a mammalian cell line : comparison with D2 receptor.
Eur. J. Pharmacol.225: 331-337. [PMID:1354163]
35. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. (1990)
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Nature347: 146-151. [PMID:1975644]
36. Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, Davis RE, Brann MR, Burstein ES. (2006)
Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation.
Mol Pharmacol70: 1974-1983. [PMID:16959945]
37. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH, Niznik HB. (1991)
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Nature350: 614-619. [PMID:1826762]
38. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ. (2003)
N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity.
Proc Natl Acad Sci U S A100: 13674-13679. [PMID:14595031]
39. Tang L, Todd RD, Heller A, O'Malley KL. (1994)
Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines.
J Pharmacol Exp Ther268: 495-502. [PMID:8301592]
40. Thomas DR, Gittins SA, Collin LL, Middlemiss DN, Riley G, Hagan J, Gloger I, Ellis CE, Forbes IT, Brown AM. (1998)
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.
Br J Pharmacol124: 1300-1306. [PMID:9720804]
41. Vanover KE, Harvey SC, Son T, Bradley SR, Kold H, Makhay M, Veinbergs I, Spalding TA, Weiner DM, Andersson CM, Tolf BR, Brann MR, Hacksell U, Davis RE. (2004)
Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-aceta mide hydrochloride]: a selective serotonin 2A receptor inverse agonist.
J Pharmacol Exp Ther310: 943-951. [PMID:15102927]
42. Wainscott DB, Sasso DA, Kursar JD, Baez M, Lucaites VL, Nelson DL. (1998)
[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor.
Naunyn Schmiedebergs Arch Pharmacol357: 17-24. [PMID:9459568]
43. Yoshio R, Taniguchi T, Itoh H, Muramatsu I. (2001)
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Jpn J Pharmacol86: 189-195. [PMID:11459121]
44. Zhu Y, Michalovich D, Wu H, Tan KB, Dytko GM, Mannan IJ, Boyce R, Alston J, Tierney LA, Li X, Herrity NC, Vawter L, Sarau HM, Ames RS, Davenport CM, Hieble JP, Wilson S, Bergsma DJ, Fitzgerald LR. (2001)
Cloning, expression, and pharmacological characterization of a novel human histamine receptor.
Mol Pharmacol59: 434-441. [PMID:11179436]